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matched sample of patientswithHbA1c greater than or equal to 7%, for a difference
of $2,713 [$285 - $5,140]. In contrast, when we examined the change in cost from
2006 to 2009 for patients who had sustained levels of HbA1c at 7% for all 3 years,
we found that total cost care for patients with sustained control decreased by
$2,207 compared to a $3,006 increase for patients without sustained control, for a
difference of -$5,214, 95%CI[-$10,163 - -$264]. CONCLUSIONS: Our study suggests
that while reducing HbA1c levels to target goalsmay not immediately result in cost
reductions, sustained HbA1c control is likely to reduce costs in a three-year time
frame.
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OBJECTIVES: Diabetic patients with chronic renal failure are at risk of developing
hypoglycemia and metabolic acidosis. The purpose of this study was to estimate
the health care resource utilization and costs associated with these complications.
METHODS: Patients covered by the Quebec provincial drug reimbursement pro-
gram (RAMQ)who had a diagnosis of diabetes, had used a hypoglycemic agent, and
who had experienced hypoglycemia or metabolic acidosis in the period from Jan-
uary 2005 to December 2010 were selected. Health care resources in terms of phy-
sician visits, hospitalization, intensive care unit stay, hospital outpatient clinic
visits, and emergency room visits were estimated for the 10-day period before and
the 30-day period after a complication event. The resources consumed during a
40-day period one year before the event, corresponding to a period without any
complication event, was deducted to estimate the incremental costs associated
with these complications. RESULTS: A total of 4889 patients had a diagnosis of
diabetes with chronic renal failure (average age 69.2 years (SD10.1)). Of these, 530
(10.8%) experienced a hypoglycemic event and 95 (1.9%) an episode of metabolic
acidosis. Estimated incremental costs of medical resources were $3859 for hypo-
glycemia and $5019 for metabolic acidosis. In both cases, hospitalization was the
major cost coponent: $2560 and $3065 for hypoglycemia and metabolic acidosis,
respectively. CONCLUSIONS: A significant proportion of diabetic patients with
chronic renal failure experienced hypoglycemia or metabolic acidosis, with sub-
stantial associated costs. Treatment options that minimize the risk of these com-
plications should be considered.
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Hypoglycemia is one of the limiting factors for achieving adequate metabolic
control in diabetic patients. Although it is well accepted that the economic burden
of diabetes is substantial, the financial impact of hypoglycaemia to patients, the
health system and society is unclear.
OBJECTIVES: To assess the economic impact associated with hypoglycemic events
through a search of the published literature in type 1 and type 2 diabetic patients
using oral antidiabetes drugs and/or insulin therapy. METHODS: An in-depth lit-
erature review was conducted, EMBASE and PubMed databases were searched
from 2005 to November 2011. A total of 24 US and European articles were retrieved.
Costs were collected according to severity of hypoglycemia: symptomatic non-
severe and severe hypoglycemia. RESULTS: Direct non-medical costs and indirect
costs are studied for symptomatic non-severe hypoglycemia, as the economic im-
pact is limited to lost work productivity, increased out-of-pocket costs mainly due
to groceries, extra test strips and transportation services. The lack of consensus of
the definition of severe hypoglycemia leads to great variation of published costs.
Total costs per severe episode (direct/indirect costs), for patients requiring assis-
tance from family members ranged from 30 to 63€, for patients needing medical
attention but not admitted to hospital overnight ranged from 274 to 489€, and for
patients requiring hospitalization ranged from 1306 to 3917€. US Study reported
mean cost per severe episode of $1087. CONCLUSIONS: No clear consensus on the
definition of severity of hypoglycemia was specified in the literature. Costs for
symptomatic or non-severe hypoglycemia are sparse and a high variation in costs
for severe hypoglycemia was observed. Hospitalization costs are the main cost
driver for severe events. The evaluation of the economic burden of severe hypo-
glycaemia needs to consider the subcategories of assistance in order to reduce
uncertainty in third payer point of view.
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OBJECTIVES:To explain differences in number of and expenditures on office-based
health care visits between insured and uninsured children.METHODS: Using four
two-year panels from the Medical Expenditure Panel Survey (MEPS) from 2004-
2008, a 1:1 nearest-neighbor-with-replacement case-control design (matching on
age category, race, region, health status, change in health status, specific MEPS
panel, and chronic condition(s)) was used to match a continuously (24-months)
uninsured (case) with a continuously insured (control) child. The Wilcoxon
matched-pairs test was used to compare the mean number of office visits and
mean expenditures between cases and controls. Then, ordinary-least-squares re-
gressionmodels to explain the size of the difference between case and controlwere
estimated, accounting for survey design. RESULTS: Out of the approximately 257
million (weighted total) children aged 0-17 across 4 MEPS panels, 4.13% had no
health-insurance coverage over the 2-year panel, while 76.95% experienced con-
tinuous coverage. The average number of office visits for uninsured children was
0.07 (p-value 0.01) less per month than that for insured children; mean expendi-
tures on these visits per month was $11.57 (p-value  0.01) less for uninsured
children. Regression predictors with statistically significant coefficients included
average healthcare status, change in health care status over the two-year panel,
age category, race, income category, and region of the country. Children whose
health status improved over the panel had a drop (p-value 0.01) in the difference
between case and control in office-based health care expenditure, relative to chil-
dren whose health status remained steady. CONCLUSIONS: Utilization of and
spending on office-based health care are significantly higher for children covered
by health insurance. Moreover, the penalty for lack of insurance can be explained
by important predictors including income, age category, and health status. The
lack-of-insurance barrier for office-based visitsmay potentially also be a barrier for
patient-centered medical homes.
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OBJECTIVES: Diabetes mellitus (DM) poses a serious public health problem world-
wide and a substantial financial burden on each national health care budget. In
Saudi Arabia, US$1.4 billionwas spent on the treatment of DM in 2010, representing
21% of the national health care expenditure; it is expected to rise to US$3 billion by
2030. This study aimed to collect up-to-date direct medical costs of managing and
treating DM-related complications to the Saudi public healthcare sector.
METHODS: A literature review was conducted using EMBASE, Medline and the
Cochrane Library databases. Data gaps were then addressed by searching grey
literature and interviewing local expert physicians. Costs were categorised into six
groups: management costs, cardiovascular complications, renal complications,
acute events, eye-disease and neuropathy/foot ulcers whichwere presented as the
first-year costs and in subsequent years following an event in 2011 US-dollars
(US$1SAR3.75). RESULTS: The highest first year costs were observed in the renal
complications group: renal transplantation (US$62,571) and haemodialysis
(US$40,000). High annual costs were also associated with the treatment of cardio-
vascular complications, ranging from US$8960 in the first year of treating myocar-
dial infarction to US$1032 for inpatient follow up in subsequent years following an
angina event. Other first-year costs of treating cardiovascular events were: stroke
(US$5973), congestive heart failure (US$4992), and peripheral vascular disease
(US$4891). The cost of an amputation procedurewasUS$3293, excluding the cost of
prosthesis (US$320), with the cost of follow-up after amputation at US$1653. The
cost of a laser eye procedurewas US$928, while the cost of a cataract operationwas
US$1669. CONCLUSIONS: The costs of managing DM-related complications per
patient could pose a significant financial burden on health care expenditure in
Saudi Arabia. This study provided reliable, up-to-date cost data that can be used to
conduct further economic evaluations of DM-related treatments in Saudi Arabia.
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OBJECTIVES: Diabetes mellitus (DM) is a chronic and degenerative disease that is
considered a public health problem in Mexico, having high impact on national
health care expenditure. The economic burden of the disease has been estimated
at 778 million US-dollars (2010). Treatment of complications represents 32.1% of
the direct costs (110 million dollars) while pharmacological treatment represents
38.7%. The objective of this study was to collect up-to-date direct medical costs
related to treatment of diabetes complications in Mexico.METHODS: A DRG cost-
ing approach was employed using recently published Mexican DRG tariffs. Data
gaps were addressed using data from the literature or by interviewing local key
opinion leaders. Annual drug-costs were calculated based on public prices (Com-
praNet). Costs were organized into 6 groups (management-costs, cardiovascular-
complications, renal-complications, acute-events, eye-disease and neuropathy/
foot ulcers). Values are presented in 2011 US-dollars as per event costs and
classified into first-year and subsequent years of the event, using an exchange rate
of 1 US$12.975MXP. RESULTS: The highest first-year costs were observed in
the renal-complications group (haemodialysis: US$33,627; peritoneal-dialysis:
US$26,703, renal transplant: US$16,004). High costswere also associatedwith treat-
ment of neuropathy (US$3040), infected foot ulcer (US$4718) and gangrene
(US$1941). The cost of an amputation procedurewasUS$4769, excluding the cost of
prosthesis (US$1515). Costs of treating cardiovascular complications ranged from
US$6689 for stroke with death within 30 days to US$1,583 for annual inpatient
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